Study of a New Twice-Daily Formula for Treating Facial Dark Spots from Melasma, Acne Scars, and Sun Spots Over 3 Months

What this Trial Is About

Researchers are evaluating a new cosmetic formula to treat facial hyperpigmentation caused by three conditions mild to moderate melasma, mild to moderate acne-induced post-inflammatory hyperpigmentation, and solar lentigo. This open, single-center study aims to assess the products effectiveness, cosmetic acceptability, and its impact on reducing stigma associated with these skin conditions. The study follows ethical guidelines and good clinical practices to ensure proper conduct and data analysis. The study involves applying the tested product twice daily, in the morning and evening, along with using sunscreen in the morning and at midday for three months. Participants are grouped based on their specific type of hyperpigmentation melasma, acne-induced hyperpigmentation without active acne, or solar lentigo. Each participant will use the product under normal conditions, with before-and-after comparisons to evaluate changes. Participants will be assessed at the start and after 84 days to measure skin changes using various pigmentation scores specific to each condition. Researchers will also use colorimetry to quantify skin color changes. Safety data will be recorded but not statistically analyzed. The study expects to include about 20 patients per group and will observe participants throughout the three-month treatment period to monitor efficacy and tolerability.

Efficacy and Tolerability of Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins